OIPE JC100 FEB 0 2 2004 PATENT & TRADEMARK OFFICE

PATENTS

IN THE UNITED STATES PATENT AND TRADMARK OFFICE

Applicants: Pratt, et al.

Serial No.: 10/679,881

Filed: October 6, 2003

Title: ANTI-INFECTIVE AGENTS

Case No.: 6998USP3

Group Art No.: 1614

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on:

Date of Deposit: January 28, 2004

Tanya Parent 1/28/04
Tanya Parent Date

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled ANTI-INFECTIVE AGENTS are the following:

1. Information Disclosure Statement;
2. Form PTO 1449, in duplicate; and
3. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

Respectfully submitted,
Pratt, et al.

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 935-7835
Facsimile: (847) 938-2623

Kalim S. Fuzail
Registration No. 45,805
Attorney for Applicants

OIPE JC100
FEB 0 2 2004
PATENT & TRADEMARK OFFICE

PATENTS

IN THE UNITED STATES PATENT AND TRADMARK OFFICE

Applicants: Pratt, et al.

Serial No.: 10/679,881

Filed: October 6, 2003

Title: ANTI-INFECTIVE AGENTS

Case No.: 6998USP3

Group Art No.: 1614

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on:

Date of Deposit: January 28, 2004

Tanya Parent 1/28/04
Tanya Parent Date

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form.

Applicants submit herewith the Form PTO-1449 listing the references cited in this Information Disclosure Statement. The listed references are available for the Examiner to review in the file of the U.S. Serial No. 10/410,853. If the Examiner needs further copies of any cited references, the Examiner is respectfully requested to contact the undersigned attorney.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

Respectfully submitted,
Pratt, et al.

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 935-7835
Facsimile: (847) 938-2623

Kalim S. Fuzail
Registration No. 45,805
Attorney for Applicants

OIPE JC1 80
FEB 0 2 2004
PATENT & TRADEMARK OFFICE

DATE: January 28, 2004 SHEET _1_ of _1_

Form PTO - 1449 (Modified)

FORM PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 6998.US.P3	SERIAL NO. 10/679,881
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT(S) Pratt, et al.	
(Use several sheets if necessary)	FILING DATE October 6, 2003	GROUP 1614
(37 CFR 1.98 (b))		

U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	3,133,918	05/19/64				
	A2	3,291,794	12/13/66				
	A3	3,499,082	03/03/70				
	A4	5,378,704	01/03/95	Weller			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS-LATION YES	TRANS-LATION NO
	B1	386435		CH			X	
	B2	0 618 209	23.12.98	EP			X	
	B3	885950		GB				
	B4	01/85172	15.11.01	WO				
	B5	02/98424	12.12.02	WO				
	B6	03/37262	08.05.03	WO				
	B7	03/59356	24.07.03	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	C1	Dhanak et al., "Identification and Biological Characterization of Heterocyclic Inhibitors of the Hepatitis C Virus RNA-dependent RNA Polymerase," Journal of Biological Chemistry 277(41); 38322-38327 (2002)
	C2	Dhanak et al., "Identification and Biological Characterization of Heterocyclic Inhibitors of the Heptitis C Virus RNA-Dependent RNA Polymerase," 9th International Meeting on HCV and Related Viruses, July 7-11, 2002; San Diego, CA; Abstract #0-3, pg. 21.
	C3	McHutchison, The American Association for the Study of Liver Diseases, Hepatitis Single Topic Conference: Hepatitis C New Drug and Clinical Trials Development: Promises and Pitfalls. Abstract #5; February 27-March 1, 2003, Chicago, IL
	C4	Ukrainets et al., "4-Hydroxy-2-Quinolones. 42*. Synthesis and biological Activity of 1-R-2-Oxo-3-(2H-1,2,4-Benzothiadiazine-1,1-Dioxid-3-Yl)-4-Hydroxyquinolines," Chemistry of Heterocyclic Compounds 36(3):346-350 (2000)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not n conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

DATE: January 28, 2004 SHEET _1_ of _1_

Form PTO - 1449 (Modified)



FORM PTO-1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
	6998.US.P3	10/679,881
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT(S) Pratt, et al.	
(Use several sheets if necessary)	FILING DATE October 6, 2003	GROUP 1614
(37 CFR 1.98 (b))		

U.S.PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	3,133,918	05/19/64				
	A2	3,291,794	12/13/66				
	A3	3,499,082	03/03/70				
	A4	5,378,704	01/03/95	Weller			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS-LATION YES	TRANS-LATION NO
	B1	386435		CH			X	
	B2	0 618 209	23.12.98	EP			X	
	B3	885950		GB				
	B4	01/85172	15.11.01	WO				
	B5	02/98424	12.12.02	WO				
	B6	03/37262	08.05.03	WO				
	B7	03/59356	24.07.03	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	C1	Dhanak et al., "Identification and Biological Characterization of Heterocyclic Inhibitors of the Hepatitis C Virus RNA-dependent RNA Polymerase," Journal of Biological Chemistry 277(41); 38322-38327 (2002)
	C2	Dhanak et al., "Identification and Biological Characterization of Heterocyclic Inhibitors of the Heptitis C Virus RNA-Dependent RNA Polymerase," 9th International Meeting on HCV and Related Viruses, July 7-11, 2002; San Diego, CA; Abstract #0-3, pg. 21.
	C3	McHutchison, The American Association for the Study of Liver Diseases, Hepatitis Single Topic Conference: Hepatitis C New Drug and Clinical Trials Development: Promises and Pitfalls. Abstract #5; February 27-March 1, 2003, Chicago, IL
	C4	Ukrainets et al., "4-Hydroxy-2-Quinolones. 42*. Synthesis and biological Activity of 1-R-2-Oxo-3-(2H-1,2,4-Benzothiadiazine-1,1-Dioxid-3-Yl)-4-Hydroxyquinolines," Chemistry of Heterocyclic Compounds 36(3):346-350 (2000)

EXAMINER	DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not n conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)